Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olmesartan medoxomil - Daiichi Sankyo Company

Drug Profile

Olmesartan medoxomil - Daiichi Sankyo Company

Alternative Names: Alteis; Benetor; Benevas; Benicar; Cardosal; CS 866; CS 866RN; CS-866DM; DE-092; Ixia; Mencord; Olmec; Olmes; Olmesartan; Olmetec; Olmighty; Olvance™; Omesar; Openvas; RNH-6270; Tensonit; Votum

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Allergan; Daewoong Pharmaceutical; Daiichi Sankyo Company; Menarini; Merck & Co; Pfizer; Sun Pharmaceutical Industries
  • Class Antihypertensives; Eye disorder therapies; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 28 Aug 2018 Daiichi Sankyo Company completes a phase II trial in Hypertension (In adolescents, In adults, In the elderly) in Japan (PO) (UMIN000015323)
  • 24 Jun 2018 Biomarkers information updated
  • 07 Dec 2017 Daiichi-Sankyo completes the phase II BOSS-Trial I trial for Hypertension in South Korea (PO) (NCT03024476)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top